Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

Schizophrenia is a serious mental illness that requires continuous and effective long-term
management to reduce symptoms, improve quality of life, and prevent relapse. Oral …

Background Long-acting injectable (LAI) formulations are not widely used in routine practice
even though they offer advantages in terms of relapse prevention. As part of a process to …

The use of long-acting injectable antipsychotics (LAIs) in schizophrenia is usually restricted
to patients in long-term treatment, who prefer them to oral antipsychotics, and to patients with …

Background For many years, long-acting intramuscular (LAI) antipsychotics have been
prescribed predominantly to chronic and severe patients, as a last resort when other …

Clinical guidelines provide evidence-based recommendations to regulate pharmacological
treatment of psychotic disorders. However, the quality of evidence, country of origin, and …

Antipsychotics are an essential component in the treatment of schizophrenia. Long-acting
injectable formulations (LAI) arose to improve adherence with the associated potential of …

Background Prescription rates for long-acting injectable (LAI) antipsychotic formulations
remain relatively low in Europe despite improved adherence over alternative oral …

Purpose Schizophrenia is a chronic and serious mental disorder characterized by
disturbances in thought, perception, and behavior that impair daily functioning and quality of …

Los antipsicóticos son un componente esencial del tratamiento de la esquizofrenia. Las
formulaciones inyectables de liberación prolongada (ILP) surgen para mejorar la …